Vigabatrin is an irreversible GABA transaminase inhibitor used as an adjunct therapy to treat refractory complex partial seizures in patients ≥2 years unresponsive to alternatives. May also be used as monotherapy to treat infantile spasms in infants 1 month to 2 years. Vigabatrin is an analog of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms.
- Mechanism
- Curator reviewed · 2 references
Gamma-aminobutyric acid (GABA) is the major inhibitory transmitter throughout the central nervous system, and the potentiation of GABAergic neurotransmission is therefore a crucial mechanism through which antiepileptic agents may combat the pathologic excitatory neurotransmission seen in epilepsy. Vigabatrin increases concentrations of GABA in the central nervous system by irreversibly inhibiting the enzymes responsible for its metabolism to succinic semialdehyde: gamma-aminobutyric acid transaminase (GABA-T).
- Primary indication
- Vigabatrin is indicated as adjunctive therapy in the treatment of refractory complex partial seizures in patients 2 years of age and older who have had inadequate responses to multiple previous treatments (i.e. not to be...Curator reviewed · 2 structured indications
- Formula / weight
- C6H11NO2 · 129.157 g/mol (avg)
- First approval
- Canada, 2000 · United States, 2009 · European Union, 2020
- Also known as
- Gamma vinyl GABA · gamma-Vinyl GABA · Vinyl gamma-aminobutyric acid
- Code names
- CPP-109 · MDL-71754 · RMI-71754
- Brand names
Resolves to
PJDFLNIOAUIZSL-UHFFFAOYSA-NSMILESNC(CCC(O)=O)C=CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Vigabatrin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account